Targeting glutamine/glutamate metabolism to improve bone disease in patients with multiple myeloma

Nicola Giuliani, MD, PhD, University of Parma, Parma, Italy, comments on the potential to target glutamine/glutamate metabolism to block osteoclast-mediated bone destruction and improve bone disease in patients with multiple myeloma, highlighting data from in vitro experiments. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.